SESSION TITLE: Lung Cancer III
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM
PURPOSE: Immunotherapy is emerging as a major modality in treating non-small cell lung cancer (NSCLC) that is not sensitive to traditional anti-cancer therapies. Because of poor immunogenicity and heterogeneity of NSCLC, there is no international recognition of the DC vaccine. NY-ESO-1 is one of the most potential antigens within all testicular Cancer antigens and because of epitope spreading, vaccines against NY-ESO1 may also lead to a development of immune responses against other antigens. So our study is aimed to develop a new model of clinical immunotherapy with NY-ESO-1 sensitized DC vaccines.